Live tape
Top 8, mentions 7d7,412NVDA1,293 mentions▲ +0.09GOOGL1,128 mentions▲ +0.04AVGO1,031 mentions▲ +0.05NKE1,013 mentions+0.02LULU956 mentions▲ +0.03TSLA894 mentions▲ +0.06META581 mentions▲ +0.05MSFT516 mentions▲ +0.06

Equity · Healthcare

SYRE

Spyre Therapeutics, Inc. · NasdaqGS

$100 +6.38% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 26 sessions
$110 $70 10 Jun 17 Jul

The line runs $75 on 10 June through $100 on 17 July, on a scale from $70 to $110. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of SYRE over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 26 sessions over that window: $75 on 10 June 2026 through $100 on 17 July 2026.

Market cap $8.8B
P/E (TTM) 61.4
52-week range $15 – $102
Avg volume 393.0K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 8, 2026

SYRE insider trades

SEC Form 4 · last 90 days · newest reported trade 2 Sep 2026
Open-market buys 0
Open-market sells 13
Net sold $16.64M
Non-trade filings 8
Date Insider Type Shares Value
02 Sep 2026 Burrows Scott L Chief Financial Officer Sell 18,232 $1.63M
02 Sep 2026 King-Jones Heidy See Remarks Sell 400 $36K
01 Sep 2026 Burrows Scott L Chief Financial Officer Sell 7,500 $655K
01 Sep 2026 King-Jones Heidy See Remarks Sell 27,999 $2.44M
01 Sep 2026 Turtle Cameron Chief Executive Officer Sell 15,000 $1.31M
07 Aug 2026 Albers Jeffrey W. Director Sell 23,000 $2.40M
03 Aug 2026 Burrows Scott L Chief Financial Officer Sell 7,500 $717K
03 Aug 2026 Turtle Cameron Chief Executive Officer Sell 15,000 $1.43M
01 Jul 2026 Burrows Scott L Chief Financial Officer Sell 7,500 $658K
01 Jul 2026 Sloan Sheldon Chief Medical Officer Sell 8,334 $731K
01 Jul 2026 Turtle Cameron Chief Executive Officer Sell 15,000 $1.32M
25 Jun 2026 Burrows Scott L Chief Financial Officer Sell 15,000 $1.31M

Showing the 12 most recent of 13 open-market trades in this window. The figures above count all of them.

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
02 Sep 2026 King-Jones Heidy See Remarks Option exercise 400 $6K
01 Sep 2026 Burrows Scott L Chief Financial Officer Option exercise 7,500 $109K
01 Sep 2026 King-Jones Heidy See Remarks Option exercise 27,999 $406K
07 Aug 2026 Albers Jeffrey W. Director Option exercise 5,000 $52K
03 Aug 2026 Burrows Scott L Chief Financial Officer Option exercise 7,500 $109K
01 Jul 2026 Burrows Scott L Chief Financial Officer Option exercise 7,500 $109K
01 Jul 2026 Sloan Sheldon Chief Medical Officer Option exercise 8,334 $229K
25 Jun 2026 Burrows Scott L Chief Financial Officer Option exercise 15,000 $218K

SYRE reported financials

SEC EDGAR XBRL

SYRE reported revenue of $0 for the fiscal year ended 31 Dec 2025. Net income over the same period was −$155.2M.

Figure Reported Period
Revenue $0 31 Dec 2025 fiscal year
Net income −$155.2M 31 Dec 2025 fiscal year
Total assets $1.2B 30 Jun 2026 at period end
Total equity $1.1B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

SYRE earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-1.09 —
31 Mar 2026 Q1 2026 $-0.74 —
31 Dec 2025 FY 2025 — —
30 Sep 2025 Q3 2025 $-1.24 —
30 Jun 2025 Q2 2025 $-1.09 —
31 Dec 2024 FY 2024 — —
30 Sep 2024 Q3 2024 $1.06 —
30 Jun 2024 Q2 2024 $0.59 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

SYRE institutional holders

SEC Form 13F

9 of the 45 institutional funds we track reported a SYRE position for the quarter ended 30 Jun 2026 — a combined $134.2M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Marshall Wace Added +612.1% shares 991,693 $88.0M
Millennium Management Added +34.1% shares 196,712 $17.5M
Balyasny Asset Management Added +165.1% shares 147,042 $13.1M
Citadel Advisors Held (±25%) −4.7% shares 103,100 $9.2M
D. E. Shaw & Co. New position 26,452 $2.3M
AQR Capital Management Held (±25%) +9.9% shares 22,937 $2.0M
Two Sigma Investments New position 12,771 $1.1M
Man Group Held (±25%) −19.2% shares 7,714 $685K
Tudor Investment Corp Trimmed −68.4% shares 2,645 $235K
Baker Bros. Advisors Exited

Source: SEC EDGAR 13F filings

SYRE fails-to-deliver

SEC CNS data

On 11 Aug 2026, 2,448 shares of SYRE failed to deliver (about $258K).

Settlement date Shares failed Notional % of shares out
11 Aug 2026 2,448 $258K 0.003%

Source: SEC fails-to-deliver (CNS) data